Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Capecitabine and Radiation in Rectal Cancer
NCT00176787Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2000
- Primary completion
- May 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Pathologic Complete Response Rate, Clinical Response Rate and 3 more. Started Oct 2000; status: terminated.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00176787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176787.